Author: Brenda Marie Rivers|| Date Published: July 27, 2020
Moderna has been awarded a potential $472M contract modification by the Biomedical Advanced Research and Development Authority to expand late-stage clinical trials of a messenger RNA-based vaccine candidate for the novel coronavirus.
BARDA’s additional funding commitment increases the potential value of the initial contract to $955M, the company said Sunday.
Under the modification, BARDA pledged funds to support Phase 3 tests of Moderna’s mRNA-1273 vaccine including a study to be conducted with 30K participants.
The biotechnology firm will perform the participant-based trials with the National Institutes of Health and the National Institute of Allergy and Infectious Diseases’ COVID-19 Prevention Trials Network.
“Encouraged by the Phase 1 data, we believe that our mRNA vaccine may aid in addressing the COVID-19 pandemic and preventing future outbreaks,” said Moderna CEO Stephane Bancel.
The company aims to deliver 500M to 1B doses of the potential COVID-19 vaccine starting next year as part of the Trump administration’s Operation Warp Speed.
Aerospace and defense technology company Merlin has closed its business combination with Inflection Point Acquisition Corp. IV, a special purpose acquisition company…
Raytheon, an RTX business, has received a potential $212.1 million cost-plus-fixed-fee contract to provide operations and maintenance services for a relocatable over-the-horizon…
Jim Kelly, senior systems engineering manager at HPE Juniper Networking, said agentic artificial intelligence could help government agencies move toward…
AeroVironment has acquired Empirical Systems Aerospace, or ESAero, a producer of unmanned aircraft systems and advanced air mobility platforms, or AAM,…
